Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Clinical trial NCT02445248 · COMPLETED

Trial details

NCT number: NCT02445248
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma (DLBCL)

Start date: 2015-07-29
Primary completion: 2022-12-22
Enrollment: 115

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.